PubMed Health⌕ Search

Biomedical subjects

V Nitsche

Publications and source records attributed to V Nitsche.

At least 19 recordsLinked to original sources
PubMed1998

Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.

The bioequivalence of 2 formulations containing spironolactone and furosemide was determined. The test preparation was Spironolacton 50 plus Heumann tablets, a new generic spironolactone preparation, developed by Heumann Pharma GmbH, the reference preparation was Osyrol 50-Lasix capsules, Hoechst AG. The study was designed as a randomized 2-period, 2-sequence, crossover study. A daily dose of 50 mg spironolactone and 20 mg furosemide was administered over 5 days to 24 healthy volunteers in the fasting state. Plasma samples were assayed for spironolactone, its 2 active metabolites canrenone and 7alpha-thiomethylspirolactone, and furosemide by HPLC. Statistical analysis was performed by ANOVA and by nonparametric methods. Because spironolactone was rapidly eliminated from plasma, its pharmacokinetics could only be evaluated with regard to maximum plasma levels. This parameter did slightly miss the criteria for bioequivalence. For canrenone and 7alpha-thiomethylspirolactone bioequivalence was given. For furosemide the test formulation was found to be equivalent concerning the extent of bioavailability. Bioequivalence with regard to maximum concentrations could not be shown. However, from the point of view of pharmacodynamics, this finding may not necessarily be of clinical relevance.

Adult↗
PubMed1997

Relative bioavailability of 3 different chlormezanone 200 mg preparations after single dose oral administration.

Eighteen male volunteers have been treated with 3 different oral formulations of chlormezanone according to a randomized 3-way change-over design. The test preparation was a tablet (Krewel), reference preparation 1 was a suspension (Krewel), and reference preparation 2 was a tablet (Muskel Trancopal, Sanofi Winthrop GmbH). All preparations contained 200 mg of chlormezanone. Divided in 3 periods the volunteers received single doses of the test and the 2 reference formulations, respectively. Blood samples have been drawn immediately prior to each administration and at 21 sampling points within 144 h after dosing. A wash-out period of 2 weeks was maintained between successive drug doses. Plasma concentrations of chlormezanone were determined by a validated reversed-phase HPLC method with UV detection, with a lower limit of quantification of 0.1 microgram/ml. The following mean values have been obtained for the test preparation: AUC0-infinity 121 micrograms x h/ml, Cmax of 2.9 micrograms/ml at 1.5 h, t1/2 38 h, after administration of the suspension: AUC0-infinity 111 micrograms x h/ml, Cmax 2.6 micrograms/ml, tmax 1.5 h, t1/2 40 h, and after administration of the reference tablet: AUC0-infinity 121 micrograms x h/ml, Cmax 3.0 micrograms/ml, tmax 1.6 h, t1/2 38 h. The test preparation shows a relative bioavailability of 109% compared to the suspension and has been proven to be bioequivalent to the reference tablet with regard to extent and rate of absorption.

Administration, Oral↗
PubMed1997

Relative bioavailability of different butamirate citrate preparations after single dose oral administration to 18 healthy volunteers.

Eighteen volunteers have been treated with different oral formulations of butamirate citrate according to 2 randomized 2-way crossover designs. In the first study (study I) the test preparation was a syrup (Demotussol Hustensirup, Demopharm), and the reference preparation was a syrup already marketed (Sinecod Sirup, Zyma SA). A test preparation (Demotussol Tabletten) was compared to a solution (Demotussol Hustentropfen) in the second study (study II). Within the 2 study periods the volunteers received single 45 mg doses of the test and the reference formulation, respectively. Blood samples have been drawn immediately prior to each administration and at 17 sampling points within 96 h after dosing. A wash-out period of 1 week was maintained between successive drug doses. The plasma concentration of one of the main metabolites, 2-phenylbutyric acid, was determined by a validated reversed-phase HPLC method with UV detection, with a lower limit of quantification of 50 ng/ml. The following mean values have been obtained in study I (syrup preparations) for the test: AUC0-infinity 46.9 micrograms x h/ml, Cmax of 1.77 micrograms/ml at 1.1 h, t1/2 28 h and after administration of the reference: AUC0-infinity 50.4 micrograms x h/ml, Cmax 1.86 micrograms/ml, tmax 1.5 h, t1/2 26 h. In study II the following mean values have been obtained for the test preparation (tablet): AUC0-infinity 54.7 micrograms x h/ml, Cmax of 1.88 micrograms/ml at 1.1 h, t1/2 27 h and for the reference (solution): AUC0-infinity 54.5 micrograms x h/ml, Cmax 1.94 micrograms/ml, tmax 1.1 h, t1/2 26 h. Both preparations have been proven to be bioequivalent to their corresponding references regarding extent and rate of absorption.

Administration, Oral↗
PubMed1997

Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.

The aldosterone antagonist spironolactone undergoes extensive and complex biotransformation. For investigation of bioequivalence of 2 oral spironolactone formulations, Spironolacton 50 Heumann and Aldactone 50, the pharmacokinetics and bioequivalence of the parent drug and 2 predominant active metabolites, canrenone and 7 alpha-thiomethylspirolactone, were determined in a 2-way crossover study in 24 young healthy male volunteers after multiple oral dosing of 100 mg once daily. Plasma samples were measured by a newly developed HPLC assay and individual pharmacokinetic parameters of the 3 compounds were calculated by use of noncompartmental techniques. Statistical analysis was performed by ANOVA and nonparametric methods. Spironolactone was rapidly cleared from plasma. Therefore, only Css,max and tss,max were determined. Concerning Css,max bioequivalence was found with 90% classical shortest confidence interval ranging from 80.7-112.4%. The intrasubject variability for Css,max was determined to be 28.1%. Higher and persisting concentrations were observed for the metabolites. For canrenone 90% classical shortest confidence intervals were calculated as 95.4-105.0% for AUCss,tau, as 92.9-105.8% for Css,max, and as 89.1-106.3% for peak trough fluctuation (PTF). In the case of 7 alpha-thiomethylspirolactone the values were 84.2-103.0% for AUCss,tau, 77.0-98.6% for Css,max, and 85.0-100.4% for PTF. For tss,max nonparametric 90% confidence intervals were determined as 0.00 to 1.50 h for spironolactone and canrenone and as -0.50 to 1.00 h for 7 alpha-thiomethylspirolactone. The intraindividual variability was below 30% for all pharmacokinetic parameters in the case of the metabolites. Thus, bioequivalence of the test and the reference formulation can be concluded. The study suggests the inclusion of parent compound and metabolites for bioequivalence testing of spironolactone formulations. Intraindividual subject variability was clearly diminished by investigating bioequivalence under steady-state conditions.

Administration, Oral↗
PubMed1996

Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug.

Twenty healthy male volunteers were treated with 2 different oral preparations of fenofibrate according to a randomized 2-way crossover design. The test preparation was Fenofibrate 250 mg retard capsules, batch No. YXF 001, provided by MTT Medical and Technological Transfer GmbH, Unterhaching, Germany. The reference preparation was Lipanthyl 250 mg retard capsules, batch No. R9110071, manufactured by Fournier Pharma, Sulzbach, Germany. On 12 consecutive days divided in 2 periods the volunteers received 6 doses of the test and reference formulation, respectively. The daily dose of 1 capsule contained 250 mg of fenofibrate and was administered together with a standardized high calory breakfast. Blood samples were taken immediately prior to each administration and at 14 points after the last administration of each period. The concentration of the pharmacologically active compound, fenofibric acid, was determined by means of HPLC with UV detection. The calibration curve was linear in the range 0.1-20.0 micrograms/ml (r = 0.99997). A lower limit of quantification of 0.1 microgram/ml was established. The following mean values were obtained after administration of the test preparation: AUC tau 184.68 microgramsh/ml; Cmax 13.11 micrograms/ml; PTF: 125.0%. After administration of the reference formulation the following values were observed: AUC tau 175.91 microgramsh/ml, Cmax 12.27 micrograms/ml, PTF: 120.0%. AUC tau, Cmax and PTF were tested for bioequivalence parametrically after logarithmic transformation. The preparations were found to be bioequivalent.

Adult↗
PubMed1995

Bioequivalence evaluation of two different oral formulations of loperamide (Diarex Lactab vs Imodium capsules).

Twenty-four healthy male volunteers were treated with two different oral formulations of loperamide according to a randomized two-way cross-over design. The test preparation was Diarex Lactab (Mepha), the reference preparation Imodium 2 mg capsules. Divided in two periods the volunteers received single 8 x 2 mg (= 16mg) doses of the test and reference formulation, respectively. Blood samples were taken immediately prior to each administration and at 14 points within 60 h after the dose. A wash-out period of 1 week was interpaused between successive drug doses. The plasma concentration of the pharmacologically active compound, loperamide, was determined by HPLC with electrochemical detection. The calibration function was linear in the range 0-10.0 ng/ml. A lower limit of quantification of 0.2 ng/ml was established. The pharmacokinetic parameters Cmax and tmax were obtained directly from plasma data. The elimination constant was estimated by log-linear regression of the measured concentrations in the terminal phase. AUC was calculated by the trapezoidal rule and extrapolated to infinity. The following mean values were obtained after intake of 16 mg loperamide as film coated tablets: AUC0 infinity 62.04 ngh/ml, Cmax 3.35 ng/ml, tmax 4.08 h, t1/2 19.66 h and after administration of the capsules: AUC0 infinity 66.56 ngh/ml, Cmax 3.98 ng/ml, tmax 4.38 h, t1/2 18.43 h. The pharmacokinetic parameters AUC0 infinity and Cmax were tested for bioequivalence parametrically (two one-sided t-tests) after logarithmic transformation of data. Differences of tmax were evaluated non-parametrically. The preparations were found to be bioequivalent and, therefore, interchangeable.

Administration, Oral↗
PubMed1991

Discrimination of wingbeat motion by bats, correlated with echolocation sound pattern.

Bats of the species Rhinolophus rouxi, Hipposideros lankadiva and Eptesicus fuscus were trained to discriminate between two simultaneously presented artificial insect wingbeat targets moving at different wingbeat rates. During the discrimination trials, R. rouxi, H. lankadiva and E. fuscus emitted long-CF/FM, short-CF/FM and FM echolocation sounds respectively. R. rouxi, H. lankadiva and E. fuscus were able to discriminate a difference in wingbeat rate of 2.7 Hz, 9.2 Hz and 15.8 Hz, respectively, between two simultaneously presented targets at an absolute wingbeat rate of 60 Hz, using a criterion of 75% correct responses. The performance of the different bat species is correlated with the echolocation signal design used by each species, particularly with the presence and relative duration of a narrowband component preceding a broadband FM component. These results provide behavioral evidence supporting the hypothesis that bats that use CF/FM echolocation sounds have adaptations for the perception of insect wingbeat motion and that long-CF/FM species are more specialized for this task than short CF/FM species.

Animals↗
PubMed1990

Quantitative determination of terbutaline and orciprenaline in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry.

A method for the determination of unconjugated terbutaline and orciprenaline in human plasma is described. The assay is based on stable isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry. An inexpensive and rapid method for preparation of stable isotope labelled analogues as well as their use in quantitative gas chromatography/mass spectrometry is shown. A highly efficient sample work-up procedure with product recoveries of more than 95% is presented. The method developed permits quantitative measurement of terbutaline and orciprenaline in human plasma down to 100 pg ml-1, using 1 ml of sample. Plasma levels of terbutaline after oral administration of 5 mg of terbutaline sulphate were estimated.

Gas Chromatography-Mass Spectrometry↗
PubMed1990

Bioavailability and pharmacokinetics of rectally administered metoclopramide.

The absolute and relative bioavailability of metoclopramide following the administration of a single suppository--test (Gastrosil) and reference preparations--containing 20 mg of the pure drug or after i.v. injection of 17.8 mg was compared in 12 sex matched healthy volunteers according to an open, three-way cross-over, intra-individual design. The metoclopramide plasma levels were determined up to 32 h following rectal administration and 24 h following intravenous application using a modified and specific HPLC-assay. The areas under the concentration-time curves were either calculated to the last time-interval measured (AUC-1) by using the trapezoidal rule or by extrapolating to infinity (AUC(0-infinity] in a model-dependent manner. Pair-differences and ratios were taken for the individual AUC-values and for the maximum plasma levels (cmax-values) at the corresponding time values (tmax-values) for test and reference formulations and tested for statistical significance. The results showed the mean AUC-1 and AUC (0-infinity)-values respectively to be 10.7% and 9.5% lower for the test suppository. The mean tmax-values were found to be 21% and 11.6% lower and the mean cmax-values were found to be about 4.3% larger than the corresponding parameters for the reference formulation. The 95% Wilcoxon confidence limits for both test and reference preparation were found to range from 80.2-108.9% for all AUC-values and to lie in the region 83.5-120.3% and 57.8-100% for the cmax- and tmax-values, respectively. Thus, with respect to the pharmacokinetic target parameters, little difference can be found between the two suppository forms each containing 20 mg metoclopramide-base and under trial in this study.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Rectal↗
PubMed1988

Femtomole analysis of diclofenac in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry using (18O2)diclofenac as internal standard.

A stable isotope dilution gas chromatography/negative ion chemical ionization/mass spectrometry assay for diclofenac in human plasma is described. The preparation of (18O2)diclofenac and its use as an internal standard for quantitative gas chromatography/mass spectrometry is shown. A sample processing and derivatization sequence with product recovery of 84.7% was found. The method presented permits quantitative measurement of diclofenac in human plasma at the lower femtomole level. Plasma levels of diclofenac after administration of diclofenac gel were estimated.

Diclofenac↗
PubMed1988

Femtomole analysis of diclofenac in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry using (18O2) diclofenac as internal standard.

A stable isotope dilution gas chromatographic/negative ion chemical ionization mass spectrometric assay for diclofenac in human plasma is described. The preparation of (18O2)diclofenac and its use as an internal standard for quantitative gas chromatography/mass spectrometry is shown. A sample processing and derivatization sequence with product recovery of 84.7% was found. The method presented permits quantitative measurement of diclofenac in human plasma at the lower femtomole level. Plasma levels of diclofenac after administration of diclofenac gel were estimated.

Diclofenac↗
PubMed1986

Pharmacokinetics and bioequivalence of different formulations of pirenzepine.

An intraindividual comparative single-dose study was carried out under carefully controlled conditions on 12 healthy volunteers in order to establish the bioavailability of 5,11-dihydro-11-[(4-methyl-piperazin-1- -yl)acetyl]-6H-pyrido[2,3b][1,4]benzodiazepin-6-one dihydrochloride (pirenzepine), the active principle of newly developed tablets (Gastricur) and suspension containing 10 mg. In an additional multiple dose, cross-over study on 12 healthy volunteers, the bioequivalence of pirenzepine was investigated after administration of the newly developed vs. commercial dose-equivalent tablets. Pirenzepine was assayed from plasma by a new, highly sensitive high-performance liquid chromatography method. A 3-compartment model was taken as a basis for the calculation of the plasma concentration curves and the pharmacokinetic parameters. Following i.v. administration, the terminal elimination half-life, t 1/2, the volume of distribution, V1, and the total plasma clearance Cl were determined to be 7.7 +/- 1.4 h, 0.255 +/- 0.057 l/kg and 263.4 +/- 56.8 ml/min, respectively. From the tablet and suspension formulation the systemic availabilities were calculated to be 33.5% and 20.3%, respectively. In the multiple dose study, both tablet forms investigated were bioequivalent.

Administration, Oral↗
PubMed1985

[The pharmacokinetics and bioequivalence of various dosage forms of ambroxol].

An intraindividual comparative single-dose study was carried out under carefully controlled conditions on 12 healthy volunteers in order to establish the bioavailability of trans-4-(2-amino-3,5-dibromobenzyl)-amino-cyclohexanol (ambroxol) the active principle of newly developed tablets and drops, in comparison to a commercial i.v. preparation. In an additional single-dose, cross-over study on 12 healthy volunteers the bioequivalence of ambroxol was investigated after administration of a newly developed vs. a commercial dose-equivalent, sustained-release dosage form. Following off-line derivatisation using formaldehyde to the corresponding tetrahydroquinazoline compound, ambroxol was assayed from plasma by high-performance liquid chromatography. A 2-compartment model was taken as a basis for the calculation of the plasma concentration curves and the pharmacokinetic parameters following intravenous injection of the drug. After i.v. administration, the terminal elimination half-life, the apparent volume of distribution and the total plasma clearance were determined to be 3.72 h, 1.52 l/kg and 565 ml/min, respectively. From the tablet and drop formulations the systemic availabilities were calculated to 73 and 81%, respectively; the mean transit times were determined to be 6.8 and 5.4 h, respectively. Both sustained-release dosage forms investigated are bioequivalent.

Adult↗
PubMed1984

Separation, isolation and identification of optical isomers of 1,4-benzodiazepine glucuronides from biological fluids by reversed-phase high-performance liquid chromatography.

A reversed-phase high-performance liquid chromatographic (HPLC) method for the determination of four separate 1,4-benzodiazepine glucuronides in urine, plasma and bile is presented. We succeeded not only in determining the single glucuronides but also in separating the enantiomers (optical isomers) of the 1,4-benzodiazepine glucuronides. The optical isomers of the glucuronides of oxazepam and cinolazepam and of two other glucuronides of benzodiazepine metabolites could be well separated. The ratio of the isomers could be evaluated. An octadecyl reversed phase was used with a mobile phase of acetonitrile and 0.01 M orthophosphoric acid. After the initial separation, the isomers were fractionated by HPLC. After treatment with beta-glucuronidase to yield the aglycone, the separated fractions were hydrolysed to the corresponding benzophenones whose identity was confirmed by HPLC. Gas chromatography and gas chromatography-mass spectrometry demonstrated that the separated glucuronides corresponded to the enantiomeric benzodiazepines. Human urine and plasma as well as rabbit urine, plasma and bile were examined.

Benzodiazepines↗
PubMed1984

Determination of codeine in human plasma by reverse-phase high-performance liquid chromatography.

A high-performance liquid chromatographic (HPLC) method for the determination of codeine in human plasma is described. The specific, precise, and sensitive method can be used to determine plasma codeine levels after administration of therapeutic doses of codeine. After purification on a C18 extraction column, codeine in the form of hydrochloride is eluted. After addition of the internal standard, the codeine is separated on a reverse-phase C18 column using a slightly alkaline mobile phase and is then determined by UV detection. The analysis takes 3.5 min per run; the limit of detection is approximately 3 micrograms/L for a 50-microL loop and 800 microL of plasma. The absolute recovery is 98.4 +/- 6.7% (n = 14) in the 10-300-micrograms/L range. Within the range, the calibration curve is linear.

Adult↗